This study aimed to compare serum ICAM-1 and VCAM-1 levels in patients with ankylosing spondylitis and psoriatic arthritis versus controls, and to examine their associations with disease activity, systemic inflammatory burden, cardiovascular risk profile, and treatment status.<h4>Methods</h4>This cross-sectional study included 154 participants recruited between 2023 and 2024, including 83 patients with AS, 40 with PsA, and 31 controls. Here, VCAM1 is linked to ankylosing spondylitis.